Summary: In 39 unselected patients with acute infective hepatitis diagnosed on clinical, epidemiological, and pathological findings, smooth muscle (S.M.) antibody was found in 87% and hepatitis-associated antigen in 33%. The incidence of S.M. antibody was highest during the first month after the onset of symptoms, and the antibody was preponderantly IgM at this stage.
Introduction
Autoantibodies in liver disease have been reported mainly in chronic active hepatitis, primary biliary cirrhosis, and cryptogenic cirrhosis (Johnson et al., 1965; Walker et al., 1965; Doniach et al., 1966) . In these liver conditions smooth muscle antibody, antimitochondrial antibody, and antinuclear factor are considered to represent a group of tissue antibodies that are "markers" of an autoimmunizing process associated with continuing liver injury (Doniach and Walker, 1969) .
In acute infective hepatitis the incidence of autoantibodies is not established. Two reports (Doniach et al., 1966; Wright, 1970) , however, have mentioned that smooth muscle antibody is present in a minority of cases. The firm association that has recently been established between some forms of acute hepatitis and-the presence in the serum of the hepatitisassociated antigen (Australia-SH antigen) (Zuckerman, 1969) has raised the question of whether a relationship exists between this antigen and autoimmune responses. In 78 patients with acute viral hepatitis Wright (1970) found no correlation between the presence of smooth muscle (S.M.) antibody and hepatitis-associated antigen, but was able to demonstrate S.M. antibody intermittently in only 19 (24%). It thus seemed important to examine the incidence of autoantibodies in more detail by testing serial serum samples from well-documented patients with acute infective hepatitis. These samples were tested for S.M. antibody, antimitochondrial antibody, and antinuclear factor.
Patients and Methods Thirty-nine unselected consecutive patients, diagnosed on clinical, -epidemiological, and pathological findings as suffering from acute infective hepatitis (Zuckerman, 1970) The patients were examined weekly during the period of the acute illness and blood samples were collected at these times. They were seen again at intervals increasing from 2 to 12 weeks. The mean number of blood samples obtained by the end of the first month after the onset of symptoms was 2.3, and over the whole period of assessment was 6. Liver biopsy specimens were obtained from 16 of the 39 patients the histological appearances being consistent with the clinical diagnosis of acute infective hepatitis.
Immunofluorescent Tests
Fluorescein-labelled antihuman globulin reagents were prepared from class-specific rabbit antihuman IgG and sheep antihuman IgM sera by reacting the globulin fraction precipitated by half saturated (NH,)2SO4 with fluorescein isothiocyanate (Isomer I) (B.D.H.) at 30 jig./mg. protein for 90 minutes at pH 9 and room temperature. Unreacted dye was removed by filtration through Sephadex G50. The classspecific reactivity of the two conjugates was confirmed by results of testing known IgG and IgM antinuclear and other tissue antibodies. Sera were tested at 1/10 dilution in duplicate with the two conjugates diluted 1/40 and 1/10 respectively. Composite cryostat sections of rat kidney, rat stomach, and rat liver were used as substrate for antimitochondrial, antismooth-muscle, and antinuclear antibodies. Sections were examined with a Reichert Zetopan microsoope, a cardioid darkground condenser being used, an HBO200 mercury vapour lamp, a BG12 3-mm primary filter, and a GG9 secondary filter.
Immunodiffusion Tests
Immunodiffusion tests were carried out by the method described by Zuckerman and Taylor (1969) , the double diffusion micro-Ouchterlony technique as modified by Prince (1968) being used. Agarose gel (0.9%) was prepared in a buffer containing 0-1M sodium chloride, 0-1M tris (hydroxymethyl) amino-methanol (pH 7.6 at 250 C.), 0.001M ethylenediaminetetra-acetic acid, and 1 mg./ml. protamine sulphate. Merthiolate was added to the gel to give a final concentration of 1/5,000.
Tests were performed in 190-mm. Sterilin plastic Petri dishes containing 15 ml. 0-9% agarose gel. A pattern of six equivalent wells surrounding a central well was used. The wells were 2-5 mm. in diameter and 4 mm. apart. Test sera were added to the peripheral wells and allowed to diffuse for 20 minutes before the addition of antiserum to the central well. The gel was kept in a moist chamber at room temperature and read daily for seven days.
The antiserum used to detect the hepatitis-associated (Australia-SH) antigen was obtained from a frequently transfused patient and gave reactions of identity with antisera anti-Au(I) (CO41177) 
Results
Smooth muscle antibody was found during the course of the illness in 34 of the 39 patients (16 female, 23 male). Hepatitis-associated antigen was found in the sera of 13 patients. The use of anti-IgM conjugate increased the number of positive S.M. antibody tests, especially during the first month. Of the 27 patients positive at this time seven were positive by IgM testing only, and all except one of the remainder had both IgG and IgM S.M. antibody. Positive staining was noticeably stronger with anti-IgM than with anti-IgG in two-thirds of the serum samples tested at this time. When S.M. antibody was found several consecutive tests were often positive.
There was no correlation between the presence of S.M. antibody and the presence of hepatitis-associated antigen, either early in the illness or later (Table I) . A striking difference was observed, however, between the incidence of S.M. antibody and the incidence of hepatitis-associated antigen when cases were considered according to possible mode of exposure to infection. While hepatitis-associated antigen was strongly associated with parenteral exposure, and was found in only one patient thought to have been infected orally, thoe mode of exposure to infection did not in any way affect the incidence of S.M. antibody (Table' II). The incidence of S.M. antibody and hepatitis-associated antigen at different intervals after the onset of symptoms is shown in Table III . For both, the highest incidence was seen during the first month, with S.M. antibody showing more than twice the frequency (82 ,) of hepatitis-associated antigen (35 0S,).
After the first month both tests became progressively less often positive, but the preponderance of S.M. antibody was still pronounced, as Table III shows. In 21 cases retested more than three months after the onset of symptoms S.M. antibody had persisted in, or had reappeared in, eight, while only 1 out of 24 cases similarly tested for hepatitis-associated antigen after this interval was positive. Antinuclear factor tNot all samples obtained could be examined by both tests.
(IgG and/or IgM) showed no association with S.M. antibody; it was found during the first month in 9 of the 28 cases positive for S.M. antibody and in two of the six cases negative for S.M. antibody. Antinuclear factor, on the other hand, was significantly correlated (P<0-01) with hepatitis-associated antigen (Table IV) , though both were not necessarily present at the same time in a given patient. After the first month antinuclear factor was less often found, but it was noted that among those patients retested more than three months after onset, seven of the eight with S.M. antibody were also positive for antinuclear factor or had previously been positive, while only 3 of the 13 cases negative for S.M. antibody at this time were or had been antinuclear factor positive. Furthermore, of the seven patients positive f,or both antinuclear factor and S.M. antibody when retested after more than three months, two were undergoing clinical and biochemical relapse, and two showed persistently abnormal biochemical tests. Patients negative for S.M. antibody on retesting after more than three months showed no clinical or biochemical abnormalities. Gocke and Kavey, 1969; Cossart and Vahrman, 1970 ). Other investigators have associated this antigen more specifically with serum hepatitis (Prince, 1968; Giles et al., 1969; Mosley et al., 1970) . Our results confirm this association with serum hepatitis, and eight of our patients in this group were known drug addicts.
These findings suggest that liver cell damage in acute infective hepatitis is a more direct stimulus to S.M. antibody production than the presence of hepatitis-associated antigen. They also suggest that the liver cell damage in acute infective hepatitis and in chronic active hepatitis engender similar immunological stimuli, since S.M. antibody now proves to) be almost as frequent an accompaniment of the former as of the latter. This role for liver cell damage is further supported by our findings that biochemical and clinical relapse in infective hepatitis seems to be accompanied by reappearance of S.M. antibody in the serum. Moreover, a positive antinuclear factor during the course of the illness may suggest persistent disease or relapse occurring. The patients will be followed further to obtain more evidence on this point.
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